实用肝脏病杂志2011，Vol.14Issue(1)：23-24,49,3.DOI:10.3969/j.issn.1672-5069.2011.01.008
替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的疗效观察
Comparison of telbivudine and adefovir dipivoxil in the treatment of patients with HBeAg-positive chronic hepatitis B
占国清 1谭华炳 1李儒贵 1李芳 1谢杏榕1
作者信息
- 1. 442000,湖北省十堰市,湖北医药学院附属人民医院肝病研究所
- 折叠
摘要
Abstract
Objective To compare the efficacy and safety of telbivudine(LdT)and ADV in the treatment of patients with HBeAg-positive CHB.Methods 175 patients with HBeAg-positive CHB were randomly divided into LdT group(n=85 cases)and ADV group(n=90 cases),and the observation was 48 weeks.Results Compared with the ADV group,the LdT group had a very lower serum HBV DNA levels (P＜0.01)and higher HBV DNA negative and ALT normalization rates at week 12,24,36 and 48 (P＜0.05 or P＜0.01);HBeAg negative or HBeAg/anti-HBe conversion and complete response in the LdT group were higher than those in the ADV group at week 12,24,36 (P＜0.05 or P＜0.01 );2 cases in LdT group and 1 case in ADV group had virological rebound at week 48.Conclusions Telbivudine has a stronger inhibition of HBV replication and has a higher HBeAg negative or HBeAg/anti-HBe conversion rates.关键词
慢性乙型肝炎/替比夫定/阿德福韦酯/疗效引用本文复制引用
占国清,谭华炳,李儒贵,李芳,谢杏榕..替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的疗效观察[J].实用肝脏病杂志,2011,14(1):23-24,49,3.
